Adrenal imaging agents: rationale, synthesis, formulation and, metabolism.
In this introductory paper on radionuclide adrenal imaging, the rationale, synthesis, formulation, and metabolism of two clinically well-established and one promisinmg adrenocortical imaging agents are reviewed. Their present clinical utility is reviewed in a separate presentation in this issue. Progress to date in developing a positive imaging agent of the adrenal medulla and tumors of chromaffin tissue will be given brief consideration because there is, as yet, no clinically successful radiolabeled adrenal medulla imaging agent.
D000311:Adrenal Glands / Q000000981:diagnostic imaging*; D000313:Adrenal Medulla / Q000201:enzymology; D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D002784:Cholesterol / Q000031:analogs & derivatives* / Q000378:metabolism; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes; D011877:Radionuclide Imaging; D013261:Sterols / Q000378:metabolism*
D004791:Enzyme Inhibitors; D007457:Iodine Radioisotopes; D013261:Sterols; D002784:Cholesterol; D004298:Dopamine